Pembroluzimab
Phase 2
Pembroluzimab is one of 5 therapeutic programs targeting HPV Positive Oropharyngeal Squamous Cell Carcinoma. It is currently in Phase 2.
1
Indications
1
Total Trials
1
Active Trials
4
Competitors
Pipeline
Status by Indication[2][1]
Indication
Competition
Competitive Landscape
4 competitors in HPV Positive Oropharyngeal Squamous Cell Carcinoma
#DrugCompanyPhaseTrials
1Keytruda
Merck & Co.Preclinical
Cisplatin Chemotherapy
GSKPhase 2
Pembroluzimab
DDana-Farber Cancer Institute
Phase 2
ATRN-119
AAprea Therapeutics
Preclinical
VB10.16
NNykode Therapeutics ASA
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]Open Targets Platform — Drug–disease associations for Pembroluzimab. EMBL-EBI & Wellcome Sanger Institute.
- [3]
Details
Drug Info
Quick Facts
- Highest Phase
- Phase 2[1]
- Company
- DDana-Farber Cancer Institute